RHOA and breast carcinoma: Previously, it has been demonstrated that P4 drives PR-A to interact with the G protein Gα13, whereas medroxyprogesterone acetate drives PR to interact with cSrc and to activate PI3K, leading to the activation of RhoA/ROCK-2 in breast cancer cell lines12.